

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/040470 A1

(51) International Patent Classification:

G01N 33/68 (2006.01) C07K 16/18 (2006.01)
C07K 16/28 (2006.01) C07K 16/42 (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2021/046774

(22) International Filing Date:

19 August 2021 (19.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/068,244 20 August 2020 (20.08.2020) US

(71) Applicant: **A2 BIOTHERAPEUTICS, INC.** [US/US];
30301 Agoura Road, Suite 210, Agoura Hills, California
91301 (US).

(72) Inventors: **WANG, Xueyin**; c/o A2 Biotherapeutics, Inc.,
30301 Agoura Road, Suite 210, Agoura Hills, California
91301 (US). **KAMB, Carl Alexander**; c/o A2 Biothera-
peutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills,
California 91301 (US). **XU, Han**; c/o A2 Biotherapeutics,
Inc., 30301 Agoura Road, Suite 210, Agoura Hills, Califor-
nia 91301 (US). **SANDBERG, Mark L.**; c/o A2 Biothera-
peutics, Inc., 30301 Agoura Road, Suite 210, Agoura Hills,
California 91301 (US). **WARSHAVIAK, Dora Toledo**; c/
o A2 Biotherapeutics, Inc., 30301 Agoura Road, Suite 210,
Agoura Hills, California 91301 (US).

(74) Agent: **CHRISTIANSEN, William T.** et al.; Cooley LLP,
1299 Pennsylvania Ave., Suite 700, Washington, District of
Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCERS




FIG. 16

(57) Abstract: The disclosure provides immune cells comprising a first activator receptor specific to CEA, and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*